Topical moisturizer with rose stem cell‐derived exosomes (RSCEs) for recalcitrant seborrheic dermatitis: A case report with 6 months of follow‐up
Open Access
- 3 June 2024
- journal article
- editorial
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 23 (10) , 3128-3132
Abstract
Introduction: Seborrheic dermatitis (SD) poses significant treatment challenges due to its chronic nature and the side effects associated with long‐term use of conventional therapies like topical corticosteroids. In the search for alternative treatments, exosomes, particularly those derived from rose stem cells (RSCEs), offer a promising avenue due to their potential in managing chronic skin conditions.Objective: This case report examines the efficacy of a topical moisturizer containing RSCEs in treating a patient with refractory SD, aiming to provide an alternative treatment pathway.Materials and Methods: A 40‐year‐old male with a long‐standing history of SD, unresponsive to traditional treatments, underwent a novel treatment regimen. This regimen included an initial topical application of 2.5 mL of RSCEs followed by a maintenance phase involving the application of a RSCE‐containing moisturizer. Clinical outcomes were assessed through the Patient's Global Assessment (PGA) and Investigator's Global Assessment (IGA) scores, along with evaluations of scaling and erythema.Results: Remarkable clinical improvement was noted as early as 1‐day post‐treatment, with significant reductions in redness, scaling, and itching. The patient experienced sustained relief throughout the 6‐month follow‐up, with a recurrence in the sixth month that was less severe than previous flare‐ups. This demonstrated not only the efficacy of RSCEs in symptom management but also their potential in extending remission periods.Conclusion: The chronic management of SD can benefit from innovative treatments like the RSCE‐containing moisturizer, as shown in this case report. While the observed outcomes are promising, indicating substantial improvements in skin condition and symptom management, larger controlled studies are necessary to validate the therapeutic potential of exosome‐containing moisturizers fully. This case underscores the need for alternative therapies in SD treatment, highlighting the role of exosomes as a viable option.Keywords
This publication has 18 references indexed in Scilit:
- Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trialJournal of the American Academy of Dermatology, 2024
- Adipose-derived stem cell exosomes for treatment of dupilumab-related facial redness in patients with atopic dermatitisJournal of Dermatological Treatment, 2023
- Exosomes Derived from Human Umbilical Cord Mesenchymal Stem Cells Alleviate Psoriasis-like Skin InflammationJournal of Interferon & Cytokine Research, 2022
- The novel mechanisms and applications of exosomes in dermatology and cutaneous medical aestheticsPharmacological Research, 2021
- Exosomal miRNA derived from keratinocytes regulates pigmentation in melanocytesJournal of Dermatological Science, 2019
- Efficacy of Oral Itraconazole in the Treatment and Relapse Prevention of Moderate to Severe Seborrheic Dermatitis: A Randomized, Placebo-Controlled TrialAmerican Journal of Clinical Dermatology, 2015
- Seborrheic dermatitis: Etiology, risk factors, and treatments:Clinics in Dermatology, 2013
- Single-blind, randomized controlled trial evaluating the treatment of facial seborrheic dermatitis with hydrocortisone 1% ointment compared with tacrolimus 0.1% ointment in adultsJournal of the American Academy of Dermatology, 2012
- Quality of life in patients suffering from seborrheic dermatitis: influence of age, gender and education levelMycoses, 2009
- Itraconazole in the treatment of seborrheic dermatitis: a new treatment modalityInternational Journal of Dermatology, 2003